Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an impact on our practice? Here is my selection of 3 abstracts presented at EULAR 2026 that identify therapeutic strategies that are well worth keeping on our radar.
Antoni Chan MD (Prof) synovialjoints
2 months ago
Ivarmacitinib (selective JAK1 inhibitor) significantly improved ASAS40 vs placebo in nr-#axSpA(39.7% vs 24.8%; p=0.006) at 12 weeks, sustained to 24 weeks. Another oral option for non-radiographic disease. Abstr OP0237 @RheumNow #EULAR2026
Janet Pope Janetbirdope
2 months ago
DR JOHN STONE gives Overview
Of
#IgG4
New non B cell depleter
#obexelimab N=194 in RCT
To add to B cell depletion w
#Inebilizumab
Off label but used also
#Rituximab
#steroids
#Immunesuppressives
Other investigational drugs
Ex #JAKi
#EULAR2026 @RheumNow
#OP018 #RULARbest https://t.co/Y4saGYcdww
Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).
Nelly ZIADE 🍀 Nellziade
2 months ago
💉 Does bimekizumab work in real-world PsA?
YES - EuroSpA: 76% retention at 6months
46% DAPSA LDA in 787pts across 12 registries
#OP0185 #EULAR2026 @RheumNow https://t.co/TXS3r9mZXB
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 POS0079 Phase I study of “Off-the-Shelf” CD19 CAR-T FT819 in N=13 #SLE pts with/-out LN reported favourable efficacy and safety particularly with Bendamustine conditioning. Advantages: scalable and requires minimal or no conditioning. Will move on to Phase II @RheumNow https://t.co/2rt646Qf0T
Bella Mehta bella_mehta
2 months ago
Oral GLP1s now coming to the market-Peptide based (can be given only on empty stomach),
Non peptide based (can be given anytime). Know about s/e and contraindications.
May have Rheumatic diseases indications soon. Imp for rheumatologists to be familiar.
#EULAR2026 @RheumNow https://t.co/KNudYN29PT
sheila RHEUMarampa
2 months ago
Prof. Wittmann discusses the current tx for CLE using a stepwise approach.
Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage.
Advocate for smoking cessation!
@Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 OP022 We need to think beyond proteinuria to assess activity & response in #lupusnephritis. ReBioLup study showed 67% of patients with persistent histologic activity at 12 months (NIH=>4) still met criteria for complete clinical response @RheumNow https://t.co/bRFNrNLjJX
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 OP0170 Progress of CAR-T in myositis? Phase 1 of rese-cel autologous CD19 CAR-T (advantage: humanised, 4-1BB Co-stimulatory Domain to enhance cells expansion) showed no safety signals and early efficacy in 4 IIM subtypes. Both anti-synthetase pts relapsed @RheumNow https://t.co/QisldedCti
Aurelie Najm AurelieRheumo
2 months ago
Leflunomide is not associated w/ incident or progressive ILD
Longitudinal CT Study 184 RA pts
LEF exposure inversely asso w/ new lung involvement
#POS062 #EULAR2026 @RheumNow https://t.co/LBrfycalLf
Aurelie Najm AurelieRheumo
2 months ago
SCOOT study oral split-dose vs SC MTX RA
Primary outcome EULAR mod/good response wk16
Non-inferiority NOT met
EULAR good response lower with oral split-dose OR 0.53
ACR50 lower with oral split-dose OR 0.51
Safety oral split-dose Higher transaminitis (>2× ULN)
3 serious AEs https://t.co/c8etFKtGwo
Jiha Lee JihaRheum
2 months ago
TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205
